
The Best Tech ETF to Invest $2,000 In Right Now
Investors have become drawn to all things related to artificial intelligence (AI). Some think this revolutionary technology can fundamentally change our society and economy, boosting productivity and providing a bump to GDP. Time will tell.
For those investors who want exposure to these types of companies, which only look like they'll be more important contributors to our economy in the future, perhaps an exchange-traded fund (ETF) is the solution. In fact, there's one AI ETF that I believe is a smart choice for a $2,000 investment right now.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »
It has been a huge winner in the past. And it could continue this streak in the years ahead. Here's what investors need to know.
Owning the most dominant enterprises
One benefit of owning an ETF is that investors can skip picking individual stocks. You don't have to spend hours reading SEC filings, listening to earnings calls, or creating complex financial models. Plus, there isn't any ongoing research requirement. It's a laid-back approach, which is advantageous.
The other obvious perk is that investors get broad diversification. And with the Invesco QQQ Trust (NASDAQ: QQQ), there is lots of exposure to the AI boom. Just look at the top holdings in this monster ETF. Eight of the top 10 positions are heavily involved in some way, shape, or form to AI. This group includes Microsoft, Nvidia, Apple, Amazon, Broadcom, Meta Platforms, Tesla, and Alphabet.
At a high level, these companies provide cloud computing platforms, graphics-processing units, software, advertising tools, and other high-value products and services that all directly tie into AI. And given their vast financial resources, they are in powerful positions to invest ridiculous amounts of capital to stay ahead of the curve. For instance, Microsoft's capital expenditures are projected to total $80 billion this year, mainly for AI-related infrastructure.
In total, the Invesco QQQ Trust contains 100 of the largest nonfinancial stocks that trade on the Nasdaq stock exchange. But not all of them have to do with AI. Costco, the ninth-biggest holding, is a perfect example. However, the top 10 holdings represent half of the assets, so AI is the driving force.
Tremendous returns at a cheap price
In the past decade, the Invesco QQQ Trust has generated a total return of 418%. This gain trounces the rise of the more widely followed S&P 500 (SNPINDEX: ^GSPC). A $2,000 investment in the QQQ in late June 2015 would be worth almost $10,400 today. The success of those previously mentioned enterprises, with their growth opportunities, innovative and disruptive cultures, rising profits, and economic moats, helped to support investment gains.
You'd be forgiven for thinking that the fees are high for this ETF. The Invesco QQQ Trust charges an expense ratio of just 0.2%. On a $2,000 investment, only $4 is directed to paying the asset manager to handle its various expenses. That's a favorable setup.
Investors should set realistic expectations
It can be easy to extrapolate past returns into the future. But that's not a guarantee. While it's possible that the Invesco QQQ Trust generates another 418% total return in the next decade, investors should be prepared for lower gains.
If the global economy operates with higher interest rates than it had for most of the past decade, this could pressure GDP growth. At the same time, that could get in the way of higher stock market returns. This is something to keep in mind.
However, by adding the QQQ to your portfolio, you're ensuring adequate exposure to what might be one of the most important technological trends in history.
Should you invest $1,000 in Invesco QQQ Trust right now?
Before you buy stock in Invesco QQQ Trust, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Invesco QQQ Trust wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $713,547!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $966,931!*
Now, it's worth noting Stock Advisor 's total average return is1,062% — a market-crushing outperformance compared to177%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of June 23, 2025
Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Randi Zuckerberg, a former director of market development and spokeswoman for Facebook and sister to Meta Platforms CEO Mark Zuckerberg, is a member of The Motley Fool's board of directors. John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Neil Patel has positions in Invesco QQQ Trust. The Motley Fool has positions in and recommends Alphabet, Amazon, Apple, Costco Wholesale, Meta Platforms, Microsoft, Nvidia, and Tesla. The Motley Fool recommends Broadcom and recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Globe and Mail
12 minutes ago
- Globe and Mail
AMAT's New R&D Hub in 2026: Will EPIC Push It Ahead in Chips?
Applied Materials AMAT is betting big on innovation with its new EPIC Center, expected to begin operations in the first half of 2026. EPIC, short for Equipment and Process Innovation and Commercialization, will be the largest and most advanced research & development (R&D) facility of its kind. The research facility will also be the centerpiece of Applied Materials' high-velocity co-innovation model. The EPIC Center is designed to shorten learning cycles and accelerate customer time-to-market. What sets EPIC Center apart is deep customer integration. Applied Materials plans to co-locate teams from top chipmaking companies directly inside the facility to jointly develop solutions for technologies like gate-all-around transistors, backside power delivery, and advanced packaging. The EPIC Center lab will mark an extension to Applied Materials' EPIC Platform, which is a collaborative ecosystem designed to accelerate innovation and commercialization in the semiconductor industry. EPIC Center is not a standalone effort toward enhancing R&D capabilities. Earlier in June, the company extended its collaboration with CEA-Leti to accelerate innovation in specialty semiconductors. The joint lab with CEA-Leti in France will focus on chips serving the Internet of Things, Communications, Automotive, Power and Sensors market and energy-efficient artificial intelligence (AI) infrastructure. The extended longstanding collaboration is expected to further complement Applied Materials' EPIC Platform's leading-edge roadmap. With the opening of EPIC Center, Applied Materials will be able to work with customers on several technology nodes ahead of production. The company believes that offering integrated technology platforms helps boost profitability and strengthens its position as a strategic partner with its customers. How Competitors Fare Against AMAT ASML Holding ASML continues to work directly with customers to improve its Extreme Ultraviolet (EUV) lithography machines. In the first quarter of 2025, ASML Holding stated that it is placing its newest systems into customers' R&D labs to test and improve the tools together. ASML Holding shared that some of its customers have already seen up to 60% faster cycle times and fewer process steps, dropping from about 40 to under 10, using its High NA EUV system. Lam Research LRCX is also helping customers speed up chip development. In the third quarter of fiscal 2025, Lam Research signed new customer deals for its virtual fabrication platform, SEMulator3D, which helps users to test new technologies before committing to physical production. Lam Research is also working closely with customers on gate-all-around nodes and backside power distribution, both of which are key parts of next-generation chips. AMAT's Price Performance, Valuation and Estimates Shares of Applied Materials have gained 13.2% year to date compared with the Electronics - Semiconductors industry's growth of 13.8%. AMAT YTD Price Return Performance Image Source: Zacks Investment Research From a valuation standpoint, Applied Materials trades at a forward price-to-sales ratio of 4.92X, lower than the industry's average of 8.67X. AMAT Forward 12-Month P/S Ratio The Zacks Consensus Estimate for Applied Materials' fiscal 2025 and 2026 earnings implies year-over-year growth of 9.5% and 5.5%, respectively. The estimates for fiscal 2025 and 2026 have been revised upward in the past 30 days. Applied Materials currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Zacks Names #1 Semiconductor Stock It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report ASML Holding N.V. (ASML): Free Stock Analysis Report Lam Research Corporation (LRCX): Free Stock Analysis Report Applied Materials, Inc. (AMAT): Free Stock Analysis Report


Cision Canada
16 minutes ago
- Cision Canada
Oncology Innovation Just Hit a Turning Point -- Here's What to Watch
VANCOUVER, BC, June 30, 2025 /CNW/ -- USA News Group News Commentary – The oncology landscape is being pulled in two directions. On one hand, U.S. cancer death rates continue to decline. On the other, global cases are expected to rise sharply —while early-onset diagnoses in younger patients are climbing at a troubling pace. At the same time, proposed federal budget cuts threaten to slash funding for the National Cancer Institute by up to 40%, raising concerns about the future of publicly funded research. With public resources under pressure, much of the innovation burden is shifting to the private sector, where a new generation of biotechs is stepping up—including Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Cellectar Biosciences, Inc. (NASDAQ: CLRB), Intensity Therapeutics, Inc. (NASDAQ: INTS), Accuray Incorporated (NASDAQ: ARAY), and Erasca, Inc. (NASDAQ: ERAS). Industry analysts now estimate the global oncology drug market could surpass US$900 billion by 2034, fueled by rising demand for precision diagnostics and immune-driven treatments. For investors, the sector represents a timely opportunity to support the next wave of cancer-fighting innovation. Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) has further strengthened its executive team with the appointment of Andrew Aromando as Chief Business Officer, signaling an intensified focus on business development and strategic partnerships. Aromando brings more than 30 years of biopharma experience and—alongside recently appointed CEO Jared Kelly—previously played a central role in Ambrx Biopharma's $2 billion acquisition by Johnson & Johnson. His arrival marks a leadership pivot aimed at unlocking value from pelareorep through late-stage development and corporate activity. "Andrew's experience will be invaluable as we pursue aggressive clinical and business development strategies to maximize the value of pelareorep on an accelerated timeline," said Kelly. "He is a proven industry leader with a successful track record of navigating complex transactions and partnerships and an outstanding addition to our executive team." In his new role, Aromando will lead global business development and help shape the company's corporate, clinical, and regulatory strategies. Among his top priorities will be optimizing the value of pelareorep's clinical data across multiple tumor types, including pancreatic, breast, and anal cancers. "I'm thrilled to join Oncolytics at such a pivotal moment in its evolution," said Aromando. "With promising data in difficult-to-treat cancers and a compelling body of clinical evidence in over 1,100 patients, I believe the Company is uniquely positioned to deliver meaningful value to patients and other stakeholders in the near term." Aromando has held senior leadership roles at oncology-focused biopharmas and global service firms, with emphasis on strategic planning, portfolio optimization, and product commercialization. He holds a BA from The College of New Jersey and an MA from Rutgers University. Kelly added, "Pelareorep's clinical data across multiple tumors is striking and represents the potential for a true backbone immunotherapy to address many in-need indications. The data show pelareorep creates a robust immune response in hard-to-treat cancers and improves survival in populations where prior therapies have failed." Together, Kelly and Aromando are spearheading a strategy to advance pelareorep through late-stage development while maintaining capital discipline and strategic flexibility. The program continues to yield data supporting its potential across a range of aggressive cancers. Pelareorep currently holds FDA Fast Track designation for two indications— metastatic pancreatic ductal adenocarcinoma (mPDAC) and HR+/HER2- metastatic breast cancer (mBC) —underscoring regulatory interest in the program. Across clinical trials, the viral-based immunotherapy has demonstrated immune activation, synergy with checkpoint inhibitors and chemotherapy, and encouraging efficacy in heavily pretreated patients. In mPDAC, a Phase 2 cohort reported objective response rates (ORR) above 60% in tumor-evaluable patients, well above historical benchmarks. Survival outcomes at two years also exceeded expectations. In HR+/HER2- mBC, randomized Phase 2 trials (IND-213 and BRACELET-1) showed overall survival trends supporting continued development. In anal cancer, a Phase 2 cohort combining pelareorep with a checkpoint inhibitor produced partial or complete responses that surpassed historical rates for checkpoint monotherapy—further hinting at pelareorep's broad applicability. With multiple cohorts progressing in the GOBLET study, including an externally supported pancreatic cancer arm, Oncolytics appears well-positioned to maintain clinical momentum while executing on strategic growth. Notably, prior to the appointments of Kelly and Aromando, Oncolytics presented new GOBLET data at the 2025 ASCO Annual Meeting, demonstrating pelareorep's ability to activate both innate and adaptive immune responses in metastatic pancreatic cancer. With compelling clinical evidence and new leadership in place, Oncolytics is moving forward with renewed purpose—advancing its lead asset and aligning operations for future partnership and commercialization opportunities. In other recent industry developments and happenings in the market include: Cellectar Biosciences, Inc. (NASDAQ: CLRB) has entered a multi-year supply agreement with Nusano to secure iodine-125 and actinium-225 for its radiotherapeutic programs. These isotopes will support clinical development and potential commercial needs of CLR 125 for triple-negative breast cancer and CLR 225 for pancreatic cancer. "Securing a reliable supply of both iodine-125 and actinium-225 is a critical milestone in advancing our targeted radiotherapy programs," said James Caruso, CEO of Cellectar. "This agreement ensures uninterrupted access to these essential isotopes, providing the necessary clinical development supply for our innovative clinical stage programs, including CLR 125 for triple negative breast cancer and CLR 225 for pancreatic cancer." I-125 and Ac-225 will be produced at Nusano's next-generation radioisotope production facility in Utah. Intensity Therapeutics, Inc. (NASDAQ: INTS) reported that the first patients treated with INT230-6 in its Phase 2 INVINCIBLE-4 trial for early-stage triple-negative breast cancer showed high levels of tumor necrosis after just two injections—prior to beginning standard immunochemotherapy. "We are excited to see that INT230-6 is achieving meaningful levels of necrosis in patients with evidence of immune activation," said Lewis H. Bender, President and CEO of Intensity. "TNBC Patients who have no live cancer in their tumor or nodes at the time of surgery have a significantly improved event-free survival advantage compared to those who do not have a pathological complete response." MRI scans revealed substantial necrosis with minimal residual cancer visible, suggesting a promising local tumor response. The study aims to improve pathological complete response rates, which are strongly linked to better outcomes in this aggressive cancer type. Accuray Incorporated (NASDAQ: ARAY) recently presented new long-term data at ESTRO 2025, showing that its CyberKnife System continues to deliver beneficial outcomes in treating men with prostate cancer. The studies indicate the system's accuracy and precision enable treatment of high-risk disease, as well as recurrent prostate cancer following prostatectomy, with stereotactic body radiation therapy (SBRT), expanding access to a non-invasive, short course of care to more men. "At this year's ESTRO meeting important analyses of real-world evidence (RWE) underscored the benefits of our unique robotic and helical platforms, reaffirming their use as patients' primary care option or along with other modalities such as surgery, chemotherapy or immunotherapy," said Suzanne Winter, president and CEO of Accuray. "Stand out studies focused on the company's CyberKnife System for the treatment of prostate cancer, building on a robust body of clinical data supporting its use and confirming the durability and quality of life after 10 years post-treatment." Erasca, Inc. (NASDAQ: ERAS) has received FDA clearance for an investigational new drug (IND) application for ERAS-4001, a potential first- and best-in-class pan-KRAS inhibitor targeting KRAS-mutant solid tumors. "Our RAS-targeting franchise continues to meaningfully advance, and now with clearance of our IND for ERAS-4001, we are excited to advance both ERAS-4001 and ERAS-0015 into the clinic ahead of our guidance," said Jonathan E. Lim, M.D., Erasca's Chairman, CEO, and Co-Founder. "ERAS-4001 targets multiple KRAS mutations as well as wildtype KRAS but spares HRAS and NRAS, potentially enabling a better therapeutic window relative to pan-RAS inhibitors. We believe these attributes offer a differentiated approach that can overcome treatment resistance to pan-RAS and mutant-selective KRAS inhibitors and address unmet needs for the 2.2 million people diagnosed annually worldwide with KRASm tumors." The company will evaluate the therapy in its Phase 1 BOREALIS-1 trial, with initial monotherapy data expected in 2026. Preclinical data showed potent activity against multiple KRAS mutations while sparing HRAS and NRAS, supporting a differentiated therapeutic window. DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

National Post
17 minutes ago
- National Post
Morgan Stanley Wins Two 2025 Celent Model Wealth Manager Awards for Technology Innovation in Wealth Management
Article content NEW YORK — Morgan Stanley (NYSE: MS) announced today that it has won two 2025 Celent Model Awards recognizing the Firm's innovative use of technology. The Firm secured Model Wealth Manager Awards for its SMA Matching and Transition Analysis Tools in the Data and Analytics category and for its AI @ Morgan Stanley Debrief in the Emerging Technologies category. Article content 'As our teams are continuously innovating and sourcing technology to push the industry forward, it's an honor to be recognized by Celent,' said Jed Finn, Head of Morgan Stanley Wealth Management. 'These awards validate our commitment to leverage technology to build a differentiated platform for our Financial Advisors that helps them grow their practice while effectively meeting the evolving and increasingly complex needs of our wealth clients.' Article content Celent's Model Wealth Manager awards recognize best practices of technology usage in different areas critical to success in wealth management and is the premier award that a financial firm in the industry can receive from Celent. Article content Morgan Stanley's SMA Matching and Transition Analysis Tools enable Advisors to quickly understand where clients' current portfolios have overlapping holdings or positions with Morgan Stanley or external asset manager solutions. The Transition Analysis Tool generates a report that evaluates potential tax implications of transitioning into those managed portfolios. The tools paired together give Advisors and clients a comprehensive understanding of the risk and tax impacts of different transition scenarios. Since launch, Advisors have executed over 20,000 Transition Analyses and generated over 5,000 transition reports for clients and prospects. Article content The AI @ Morgan Stanley Debrief tool leverages GenAI to assist Financial Advisors in Zoom meetings by taking notes, providing summaries, generating follow-up email drafts, and importing call information into clients' CRM profiles. With notetaking off the table, Financial Advisors are able to be fully engaged in meetings and quickly move onto their next tasks all while clients receive comprehensive notes with next steps. Morgan Stanley's team developed, piloted, and rolled out the solution to all its Financial Advisors. Article content This announcement comes on the heels of 2024 awards, where Morgan Stanley Wealth Management won a Model Wealth Manager Award for its AI @ Morgan Stanley Assistant in the Essential and Emerging Technologies category, a Model Wealth Manager Award for its Fractional Share program in the Personalization category, and a Model Risk Manager Award for its Portfolio Risk Platform in the Data and Analytics category. Article content For more information about Morgan Stanley's Celent Award honors as well as a full list of this year's honorees, please visit here. Article content About Morgan Stanley Wealth Management Article content Morgan Stanley Wealth Management, a global leader, provides access to a wide range of products and services to individuals, businesses, and institutions, including brokerage and investment advisory services, financial and wealth planning, cash management and lending products and services, annuities and insurance, retirement and trust services. Article content About Morgan Stanley Article content Morgan Stanley (NYSE: MS) is a leading global financial services firm providing a wide range of investment banking, securities, wealth management and investment management services. With offices in 42 countries, the Firm's employees serve clients worldwide including corporations, governments, institutions and individuals. For further information about Morgan Stanley, please visit Article content The Celent Model Wealth Manager 2025 Awards for Data and Analytics and Essential and Emerging Technologies were granted to Morgan Stanley Smith Barney LLC ('Morgan Stanley') following an evaluation process conducted by Celent analysts. To be considered for this award, Morgan Stanley submitted Model Wealth Manager 2025 Nomination Award Worksheets to Celent on or about January 30, 2025. Celent judged each submission on three criteria: (1) Measurable business benefits of live initiatives; (2) degree of innovation relative to the industry; and (3) technology or implementation excellence. In order to win, the initiatives must demonstrate clear business benefits, innovation, and technology or implementation excellence. Article content Celent does not receive compensation from the participating firms in exchange for the award and Morgan Stanley did not pay a fee to Celent in exchange for the award. Morgan Stanley is not affiliated with Celent. Based on their submission on January 30, 2025 for Celent's 2025 Model Awards program, Celent granted Morgan Stanley their awards in June, 2025 and publicly shared the news in June, 2025. Celent is a global financial services research and advisory firm and is responsible for determining the recipient of this award. Article content Morgan Stanley does not provide tax or legal advice. Financial Advisors should encourage their clients to consult his/her personal tax and/or legal advisor to learn about any potential tax or other implications that may result from acting on a particular recommendation. Article content Morgan Stanley provides certain products or services supported by AI via an arrangement with OpenAI LLC (OpenAI), an unaffiliated party. Morgan Stanley employees using such products or services are bound by all applicable policies and procedures. Morgan Stanley is not responsible for products and service offered by OpenAI on a basis separate from its arrangement with Morgan Stanley. Article content The Portfolio Analysis report ('Report') is generated by Morgan Stanley Smith Barney LLC's ('Morgan Stanley') Portfolio Risk Platform. The assumptions used incorporate portfolio risk and scenario analysis which is powered by BlackRock's Aladdin Wealth, a financial technology and risk analytics provider that is independent of Morgan Stanley. Aladdin Wealth's role is limited to providing risk analytics to Morgan Stanley and is not acting as a broker-dealer or investment adviser, nor does it provide investment advice with respect to the Report. Morgan Stanley has validated and adopted the analytical conclusions of these risk models. Article content This material has been prepared without consideration of the investment objectives, risk tolerance or financial circumstances of any specific investor. Before making a recommendation, the Financial Advisor or Private Wealth Advisor must have a reasonable basis for such a recommendation, and take into account the client's circumstances, objectives and risk tolerance to ensure it is appropriate for the client. Article content Article content Article content